Reliability of diagnostic imaging after orchiectomy alone in follow-up of clinical stage I testicular carcinoma: Excessive cost with potential risk

J. D. Tesoro-Tess, G. Pizzocaro, F. Zanoni, L. Balzarini, E. Ceglia, R. Petrillo, R. Musumeci

Research output: Contribution to journalArticle

Abstract

From 1981 to 1984, 86 consecutive patients with previously untreated nonseminomatous testicular carcinoma were classified as clinical radiological stage I and treated with orchiectomy alone. The follow-up program included chest x-ray and lymphangiography (LAG) every month and abdominal computed tomography (CT) bimonthly. All patients were followed for 15 to 63 months after orchiectomy (median 32 mo.). Metastases developed in 23 patients (26.7%) and in 13/23 there was retroperitoneal lymphadenopathy. Time of relapse after orchiectomy ranged from 2 to 36 months (median 7 mo.) with a shorter interval for chest (4 mo.) compared with retroperitoneal metastases (7 mo.). Lung metastases were readily identified at an early stage (5cm at time of diagnosis. LAG detected metastases in 8/11 patients (72.7%), abdominal CT in 8/10 (80%), and both together (LAG and CT) 7/8 (87.5%). In clinical stage I nonseminomatous testicular carcinoma, the high incidence of concomitant but often asymptomatic regional and distant metastases and the relatively high cost and inconvenience of follow-up using abdominal CT imaging, LAG and chest x-ray suggest that orchiectomy is best combined with retroperitoneal node dissection at time of initial presentation to insure more accurate and safe staging of tumor dissemination.

Original languageEnglish
Pages (from-to)161-165
Number of pages5
JournalLymphology
Volume20
Issue number3
Publication statusPublished - 1987

    Fingerprint

ASJC Scopus subject areas

  • Immunology

Cite this

Tesoro-Tess, J. D., Pizzocaro, G., Zanoni, F., Balzarini, L., Ceglia, E., Petrillo, R., & Musumeci, R. (1987). Reliability of diagnostic imaging after orchiectomy alone in follow-up of clinical stage I testicular carcinoma: Excessive cost with potential risk. Lymphology, 20(3), 161-165.